Intelligence Platform

Patents

Browse 379 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 7902168

Compositions and methods for inhibiting expression of Nav1.8 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7893224

Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7888498

Compositions and methods for inhibiting expression of IKK-B gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7875711

Compositions and methods for inhibiting expression of XBP-1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 25 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 20 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7871985

Compositions and methods for inhibiting expression of factor VII gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 18 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 13 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7868160

Compositions and methods for inhibiting expression of anti-apoptotic genes

Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 11 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 06 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7846908

RNAi modulation of TGF-beta and therapeutic uses thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 07 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7846907

Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 07 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7829693

Compositions and methods for inhibiting expression of a target gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 09 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7812150

RNAi modulation of Aha and therapeutic uses thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 12 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 07 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7790878

RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 07 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7786290

Double-stranded ribonucleic acid with increased effectiveness in an organism

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 31 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 26 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7772387

Oligonucleotides comprising a modified or non-natural nucleobase

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 10 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7772200

iRNA agents targeted to the Rho-A gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 10 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7763590

Compositions and methods for inhibiting expression of a mutant gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 27 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7759320

Compositions and methods for inhibiting expression of a gene from the Ebola

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 20 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7749978

Compositions and methods for inhibiting expression of Huntingtin gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 06 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7745608

Modified iRNA agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 29 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 24 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7745418

Compositions and methods for inhibiting viral replication

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 29 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 24 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7737265

RNAi modulation of HIF-1 and therapeutic uses thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 15 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 10 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7723317

RNAi modulation of ApoB and uses thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue May 25 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 20 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7723512

Oligonucleotides comprising a non-phosphate backbone linkage

Alnylam Pharmaceuticals, Inc. · Granted Tue May 25 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 20 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7718629

Compositions and methods for inhibiting expression of Eg5 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue May 18 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 13 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7691824

Compositions and methods for inhibiting expression of a gene from the JC virus

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 06 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted